
Cancel anytime
- Chart
- Upturn Summary
- Highlights
Upturn AI SWOT
- About
Direxion Daily S&P Biotech Bull 3X Shares (LABU)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: LABU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type ETF | Historic Profit -12.46% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | ETF Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Volume (30-day avg) - | Beta 2.3 | 52 Weeks Range 32.42 - 151.80 | Updated Date 06/29/2025 |
52 Weeks Range 32.42 - 151.80 | Updated Date 06/29/2025 |
Upturn AI SWOT
Direxion Daily S&P Biotech Bull 3X Shares
ETF Overview
Overview
The Direxion Daily S&P Biotech Bull 3X Shares (LABU) seeks daily investment results, before fees and expenses, of 300% of the performance of the S&P Biotechnology Select Industry Index. It offers leveraged exposure to the biotech sector, targeting short-term gains through magnified returns.
Reputation and Reliability
Direxion is a well-known issuer of leveraged and inverse ETFs, recognized for its specialized investment products. The firm has a reasonable track record, but its leveraged products are known to be high-risk.
Management Expertise
Direxion's management team has expertise in developing and managing complex investment strategies, specifically leveraged and inverse funds.
Investment Objective
Goal
To seek daily investment results, before fees and expenses, of 300% of the performance of the S&P Biotechnology Select Industry Index.
Investment Approach and Strategy
Strategy: The ETF employs a leveraged strategy, aiming to magnify the daily returns of the S&P Biotechnology Select Industry Index. This is achieved through derivatives and other leveraged instruments.
Composition The ETF primarily holds financial instruments (derivatives) designed to provide 3x leveraged exposure to the underlying index, with some allocation to equity to meet regulatory requirements. The composition changes daily based on the leverage target.
Market Position
Market Share: LABU has a significant market share among leveraged biotech ETFs, although its overall sector share is influenced by the size of non-leveraged biotech ETFs.
Total Net Assets (AUM): 653493727
Competitors
Key Competitors
- ProShares Ultra Nasdaq Biotechnology (BIB)
- ProShares UltraPro Nasdaq Biotechnology (UBIO)
- iShares Biotechnology ETF (IBB)
- SPDR S&P Biotech ETF (XBI)
Competitive Landscape
The biotech ETF landscape is competitive, including leveraged and non-leveraged funds. LABU's advantage is its high leverage, appealing to aggressive traders. However, this comes with higher risk and the disadvantage of potential significant losses due to the leveraged nature of the fund, especially compared to non-leveraged competitors like IBB and XBI.
Financial Performance
Historical Performance: Historical performance is highly volatile, with significant gains during bull markets but substantial losses during downturns. Due to its leveraged nature, it should not be considered for long-term investing.
Benchmark Comparison: Due to the 3x leverage, LABU's daily performance aims to be 3x of the S&P Biotechnology Select Industry Index, but tracking errors and compounding effects can lead to significant deviations over longer periods.
Expense Ratio: 0.95
Liquidity
Average Trading Volume
LABU has high average trading volume, indicating good liquidity.
Bid-Ask Spread
The bid-ask spread is generally tight, reflecting the ETF's high liquidity.
Market Dynamics
Market Environment Factors
Economic indicators, healthcare policy changes, FDA approvals, and overall market sentiment towards the biotech sector significantly influence LABU's performance.
Growth Trajectory
LABU's growth is tied to investor appetite for risk and the biotech sector's performance. Strategy and holdings remain aligned with its leveraged index-tracking objective, but are rebalanced daily.
Moat and Competitive Advantages
Competitive Edge
LABU's competitive advantage lies in its 3x leverage, providing amplified exposure to the biotech sector's daily performance. This makes it attractive to day traders and those seeking short-term gains. However, this high leverage also introduces a high level of risk that is amplified by the biotech sector, which is inherently volatile. Direxion's expertise in managing leveraged ETFs contributes to its competitive position.
Risk Analysis
Volatility
LABU exhibits extremely high volatility due to its 3x leverage and the inherent volatility of the biotech sector. Expect frequent and potentially large price swings.
Market Risk
LABU is highly susceptible to market risk, especially downturns in the biotech sector. The leveraged nature amplifies both gains and losses, potentially leading to significant capital erosion, particularly due to daily compounding effects.
Investor Profile
Ideal Investor Profile
LABU is suitable for sophisticated, short-term traders with a high risk tolerance and a deep understanding of leveraged ETFs and the biotech sector. It is not suitable for long-term investors.
Market Risk
LABU is designed for active traders seeking short-term gains, not for long-term investors or passive index followers. The leveraged nature makes it unsuitable for buy-and-hold strategies.
Summary
Direxion Daily S&P Biotech Bull 3X Shares (LABU) provides leveraged exposure to the biotech sector, magnifying daily gains and losses. It is a high-risk, high-reward investment vehicle designed for short-term trading strategies. The ETF's performance is heavily influenced by biotech sector trends and overall market sentiment. Due to the inherent risks associated with leveraged ETFs and the biotech industry, LABU is only suitable for experienced traders with a high risk tolerance. Investors should carefully consider the potential for significant losses before investing in LABU.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Direxion Funds Website
- ETF.com
- Yahoo Finance
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Past performance is not indicative of future results. Leveraged ETFs are high-risk investments and may not be suitable for all investors.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Direxion Daily S&P Biotech Bull 3X Shares
Exchange NYSE ARCA | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website |
The fund, under normal circumstances, invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards (GICS). The fund is non-diversified.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.